Trials / Not Yet Recruiting
Not Yet RecruitingNCT06762925
Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 450 (estimated)
- Sponsor
- Xijing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to validate the accuracy and clinical value of METTL3 as a biomarker for predicting immune therapy response in patients with urinary tract tumors through observational studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Interventions | No Interventions |
Timeline
- Start date
- 2025-01-30
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2025-01-08
- Last updated
- 2025-01-08
Source: ClinicalTrials.gov record NCT06762925. Inclusion in this directory is not an endorsement.